Blood Vessels News and Research

RSS

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

20 Aug 2010

Renin test can predict appropriate drugs for BP patients: Study

Commonly prescribed drugs used to lower blood pressure can actually have the opposite effect-raising blood pressure in a statistically significant percentage of patients. A new study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that doctors could avoid this problem-and select drugs most suitable for their patients-by measuring blood levels of the enzyme renin through a blood test that is becoming more widely available. The study appears in the online edition of the American Journal of Hypertension.

20 Aug 2010

Weight gain risk to develop endothelial cell dysfunction: Research

Mayo Clinic researchers found that healthy young people who put on as little as 9 pounds of fat, specifically in the abdomen, are at risk for developing endothelial cell dysfunction. Endothelial cells line the blood vessels and control the ability of the vessels to expand and contract.

19 Aug 2010

Cancer is the world's top 'economic killer,' report finds

The Associated Press: "Cancer is the world's top 'economic killer' as well as its likely leading cause of death, the American Cancer Society contends in a new report it will present at a global cancer conference in China this week. Cancer costs more in productivity and lost life than AIDS, malaria, the flu and other diseases that spread person-to-person, the report concludes.

18 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in The Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.

16 Aug 2010

Low socioeconomic status, stressful childhood events develop risk of cardiovascular disease

Early life adversity through poverty, social isolation or abuse in childhood is linked to heightened reactivity, which can lead to heart disease later on, a leading expert on stress and disease said Saturday."Many diseases first diagnosed in mid-life can be traced back to childhood," Karen A. Matthews, PhD, said at the 118th Annual Convention of the American Psychological Association. "Having some bad health habits in your 20s and 30s is part of the reason why people get diseases later on. However, it isn't the whole reason. The evidence shows that certain reactions to adverse childhood experiences associated with lower socioeconomic status, isolation and negative events can affect the disease process."

16 Aug 2010

CD31 positive cells have potential for treating peripheral artery disease: Research

Isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells, according to research from Emory University School of Medicine. In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.

16 Aug 2010

Susan G. Komen for the Cure, OCNA urge FDA to allow use of Avastin

Susan G. Komen for the Cure and the Ovarian Cancer National Alliance today urged the U.S. Food and Drug Administration to continue to allow the use of the drug bevacizumab, commonly known as Avastin, for metastatic breast cancer patients, noting that it is effective for some patients and warning of a chilling effect on new drug development if approval is withdrawn.

13 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

Study examines comparative value of different blood pressure lowering medications

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

Arrowhead third-quarter 2010 net loss decreases to $0.4 million

Arrowhead Research Corporation today announced financial results for its fiscal 2010 third quarter ended June 30, 2010.

13 Aug 2010

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

BioGenerator, a non-profit, seed-stage economic development funding group, today announced that it has led a round of early-stage financing for Pulse Therapeutics, Inc., a St. Louis company headquartered at the Center for Emerging Technologies. Pulse Therapeutics develops innovative magnetism-based technology to safely destroy blood clots related to ischemic stroke and deep vein thrombosis (DVT). Other investors who participated in the round were Missouri Technology Corporation (MTC), Washington University's Olin School of Business Skandalaris Student Venture Fund, and Integrated Magnetics, of Culver City, California. The funds will be used for further pre-clinical development.

12 Aug 2010

Scientists develop new imaging technique to create three-dimensional images of melanoma

Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.

12 Aug 2010

GenSpera issued additional patent for G-202

GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.

11 Aug 2010

Arrowhead Research signs option agreement for new technology platform to kill fat tissue

Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.

10 Aug 2010

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.

10 Aug 2010

Blood Vessels News and Research

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Renin test can predict appropriate drugs for BP patients: Study

Weight gain risk to develop endothelial cell dysfunction: Research

Cancer is the world's top 'economic killer,' report finds

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

Low socioeconomic status, stressful childhood events develop risk of cardiovascular disease

CD31 positive cells have potential for treating peripheral artery disease: Research

Susan G. Komen for the Cure, OCNA urge FDA to allow use of Avastin

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

Study examines comparative value of different blood pressure lowering medications

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Arrowhead third-quarter 2010 net loss decreases to $0.4 million

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

Scientists develop new imaging technique to create three-dimensional images of melanoma

GenSpera issued additional patent for G-202

Arrowhead Research signs option agreement for new technology platform to kill fat tissue

Older Americans suffer from full-blown depression: Report

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News